DUBLIN, Ireland, August 21, 2014 /PRNewswire/ --
Research and Markets(http://www.researchandmarkets.com/research/3zh3q8/global_hormone) has announced the addition of the"Global Hormone Replacement Therapy Market 2014-2018"report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones.
The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer.
The analysts forecast the Global Hormone Replacement Therapy market will grow at a CAGR of 2.51 percent over the period 2013-2018.
The Global Hormone Replacement Therapy market can be divided into three segments: Estrogen Replacement Therapy, Growth Hormone Replacement Therapy, and Thyroid Hormone Replacement Therapy.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Market Segmentation by Type of Therapy
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
17. Key Vendor Analysis
18. Other Reports in this Series
Companies Mentioned:
- Actavis plc
- Bayer AG
- Merck & Co. Inc.
- Novartis AG
- Novo Nordisk A/S
- Abbott Laboratories Ltd.
- Amgen Inc.
- ANI Pharmaceuticals Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- MylanLaboratories Inc.
- Orion Corp.
- QuatRx Pharmaceuticals Co.
- Teva Pharmaceutical Industries Ltd.
- TherapeuticsMD Inc.
For more information visithttp://www.researchandmarkets.com/research/3zh3q8/global_hormone
Media Contact:Laura Wood , +353-1-481-1716, press@researchandmarkets.net
